Article
Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics.
Leukemia & lymphoma - 1 May 2015
Fukuno Kenji, Hara Takeshi, Tsurumi Hisashi, Shibata Yuhei, Mabuchi Ryoko, Nakamura Nobuhiko, Kitagawa Junichi, Shimizu Masahito, Ito Hiroyasu, Saito Kuniaki, Moriwaki Hisataka
Abstract excerpt
The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze breakdown of the essential amino acid L-tryptophan. We applied reverse transcription-polymerase chain reaction (RT-PCR) to examine IDO mRNA expression in acute myeloid leukemia (AML) blasts, and investigated its clinical significance. We enrolled 62 patients with AML between April 2005 and March 2013. Bone...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
